comparemela.com

Latest Breaking News On - Sapience therapeutics - Page 4 : comparemela.com

Sapience Therapeutics Announces Appointment of Abi Vainstein-Haras, M D as Chief Medical Officer

/PRNewswire/ Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address.

Buenos airesDistrito federalAlices bexonBarry kappelAmy conradUniversity of buenos airesClinical program leader at tevaPrnewswire sapience therapeutics incSapience therapeutics incClinical developmentChief medical officerAbi vainstein harasBexon clinicalVice presidentSenior medical directorClinical program leader

Sapience Therapeutics to Participate in Upcoming Investor Conferences

/PRNewswire/ Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address.

Barry kappelAmy conradCapital markets healthcare private company virtual conferenceSapience therapeutics incSapience therapeuticsAnnual piper sandler healthcare conferenceMarkets healthcare private company virtualStabilized peptides engineered against regulationChief executiveInvestor contact

Sapience Therapeutics to Participate in Upcoming Investor Conferences

/PRNewswire/ Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address.

Barry kappelAmy conradCapital markets healthcare private company virtual conferenceSapience therapeutics incSapience therapeuticsAnnual piper sandler healthcare conferenceMarkets healthcare private company virtualStabilized peptides engineered against regulationChief executiveInvestor contact

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics

/PRNewswire/ Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address.

United statesBarry kappelAmy conradJim rotoloAmerican association for cancer researchHead of researchEuropean commissionPrnewswire sapience therapeutics incSapience therapeutics incMolecular cancer therapeuticsAmerican associationEnhancer binding proteinTranslational pharmacologyFast trackStabilized peptides engineered against regulationSapience therapeutics

Sapience Therapeutics Announces Publication Showcasing the Mechanism of Action and Anti-tumor Activity of ST101, a Novel and Selective Peptide Antagonist of C/EBPβ, in Molecular Cancer Therapeutics

/PRNewswire/ Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address.

United statesBarry kappelAmy conradJim rotoloAmerican association for cancer researchHead of researchEuropean commissionPrnewswire sapience therapeutics incSapience therapeutics incMolecular cancer therapeuticsAmerican associationEnhancer binding proteinTranslational pharmacologyFast trackStabilized peptides engineered against regulationSapience therapeutics

vimarsana © 2020. All Rights Reserved.